Gamma-tocotrienol modifies methylation of HOXA10, IRF4 and RORα genes in CD4+ T-lymphocytes: Evidence from a syngeneic mouse model of breast cancer

Radhakrishnan, Ammu Kutty; Rao, Jeya Seela Anandha; Subramaniam, Shonia; Ramdas, Premdass

doi:10.1016/j.crimmu.2021.10.001

Cited by 4 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Allograft models. Syngeneic models, known as allograft models, are the oldest and most often used in preclinical studies of tumor immunity and testing immunotherapy in a fully functional murine immune system capable of the immune response [49] and the complex tumor microenvironment (TME) [50]. The syngeneic models consist of mouse tumor tissues or cells expanded in vitro and implanted into genetically identical mouse strains [51].…”

Section: Transplantable Modelsmentioning

confidence: 99%

Mouse models for cancer research – current state and the perspective

Gercakova,

Poturnajova,

Tyciakova

et al. 2024

neo

View full text Add to dashboard Cite

Cancer is one of the leading causes of death worldwide. We still do not understand all the details of carcinogenesis, and effective treatment is lacking for many oncological diseases. Animal models provide an irreplaceable tool to observe the growth and spreading of neoplastic cells in an environment of living organisms, to test the efficacy of cancer treatment, side effects, and toxicity, and to study the tumor microenvironment. Mice are the most often used model organisms because of their easy handling, short reproductive period, multiple strains, and complete DNA sequencing. An ideal model should accurately recapitulate each step of tumor development. Recent techniques have established models that enable the study of different aspects of cancer, but choosing a particular model depends on the application of output data. This article aimed to review induced, transplantable, and engineered mice and highlight their significance for recent and future cancer research.

show abstract

Section: Transplantable Modelsmentioning

confidence: 99%

Mouse models for cancer research – current state and the perspective

Gercakova,

Poturnajova,

Tyciakova

et al. 2024

neo

View full text Add to dashboard Cite

show abstract

“…28,29 Tocotrienols may cause these effects by acting at the epigenome, genome or protein levels. 30 Recently, it was reported that consuming TRF can also cause changes to the gut microbiome. 31,32 In an earlier study, we reported that daily supplementation of 200 mg TRF or α-tocopherol (α Toc) did not induce significant immunomodulatory changes in healthy human volunteers in the absence of any immunological challenge.…”

Section: Introductionmentioning

confidence: 99%

Single-centre, randomised clinical trial of the immunomodulatory mechanisms of daily supplementation of palm tocotrienol-rich fraction in healthy human volunteers following influenza vaccination

Radhakrishnan,

Ahmad,

Selvaduray

et al. 2024

F1000Res

View full text Add to dashboard Cite

Background Vitamin E from palm oil, known as the tocotrienol-rich fraction (TRF), has been shown to have immune-enhancing activity. To date, only one dose of TRF (400 mg daily) has been tested in a clinical trial. The proposed study will evaluate the immune-enhancing activity effects of lower doses (200, 100 and 50 mg) in a clinical trial using an influenza vaccine as the immunological challenge. Methods A single-centre, randomised, parallel, double-blinded, placebo-controlled clinical trial with balance allocation involving five arms will be conducted. The healthy volunteers recruited will be randomly assigned to one of the arms, and they will be asked to take the respective supplements (400 mg, 200 mg, 100 mg, 50 mg of TRF or placebo) daily with their dinner. The volunteers will receive the influenza vaccine after four weeks. They will be asked to return to the study site four weeks later. A blood sample will be taken for the study at baseline, four and eight weeks. Primary outcome measures will be antibody levels to influenza, blood leucocyte profile and cytokine production. Secondary outcomes will be correlating plasma vitamin E levels with immune responses, plasma proteins and gene expression patterns. The findings from this study will be published in relevant peer-reviewed journals and presented at relevant national and international scientific meetings. Conclusions The recent world events have created the awareness of having a healthy and functional immune system. Nutrition plays an important role in helping the immune system to function optimally. This study will show the effects of lower doses of TRF in boosting the immune response of healthy individuals and also elucidate the mechanisms through which TRF exerts its immune-enhancing effects. Clinical trial registration Australian New Zealand Clinical Trials Registry (ANZCTR) [ACTRN12622000844741] dated 15 June 2022. Protocol version 2

show abstract